FIGURE 5 Mean changes (±SE) in A1c (A), body weight (B), and insulin use (C) at 26 weeks in ITT populations in the combined long-term, placebo-controlled clinical studies of pramlintide in insulin-using patients with type 2 diabetes after 26 weeks of treatment. Patients were treated with 120 ^g pramlintide b.i.d. (n = 292) versus placebo (n = 284). **P < 0.01. Source: From Refs. 30 and 31.
from baseline of —0.56 % were observed (P < 0.05). Self-monitored blood-glucose profiles at baseline and after 6 months of adjunctive pramlintide therapy revealed significantly (P < 0.05) reduced postprandial glucose concentrations, resulting in smoother daily glucose profiles (Fig. 6) (37). As in the earlier long-term clinical trials, glycemic improvements also were accompanied by significant weight loss (-2.76 kg, P < 0.05) (37).
Was this article helpful?